Bone Therapeutics recently announced it will undertake efforts to expand its offerings to include osteoblastic cell-matrix products.
These offerings, which will be used to treat large bone defects, will be a variant of the company’s osteoblastic cells within a 3-D bioprinted scaffold. The company believes this will become a favorable alternative to the current standard of care, bone autograft, according to a press release.
The company’s venture has been met with support from the government of the Walloon region, which has given Bone Therapeutics €1 million in non-dilutive, recoverable cash advances to finance the company’s efforts.
“This novel approach utilizing our allogeneic bone-forming cells within a precisely patient-tailored 3-D bioprinted structure could herald a new and highly effective treatment for large bone defects and success in a field where regenerative medicine was thought to be untenable,” Enrico Bastianelli, CEO of Bone Therapeutics, said in the release. “We are grateful to the Walloon region in supporting this important project.”